Abstract:BackgroundThe effectual immune response is crucial to defeat viral infections. However, exuberant immune response with features of macrophage activation syndrome (MAS) lead detrimental consequences in COVID-19 patients. Interleukin (IL)-18 is one of the leading cytokines in MAS which has not been studied in COVID-19.ObjectiveTo investigate the association of IL-18 with the other inflammatory markers and disease severity in COVID-19 for predicting disease prognosis.MethodsPatients with COVID-19 who had confirmed diagnosis with SARS-CoV-2 nucleic acid RT-PCR were enrolled into the study. Data on demographic and clinical characteristics, and laboratory values of CRP, ferritin, d-dimer and procalcitonin were measured on admission. Patients were followed up prospectively with a standardized approach until hospital discharge or death. Individuals were classified as asymptomatic, mild and severe pneumonia according to their clinical, laboratory and radiological characteristics. Worse outcome was defined as requirement of intensive care unit (ICU) admission or death. Blood samples were collected at enrollment and serum levels of IL-6 and IL-18 were determined by ELISA. Association between IL-18 and other inflammatory markers and prognosis were analyzed.ResultsThere were 58 COVID-19 patients (50% male) with a median age of 43 (min 22-max 81) years. Twenty age and sex matched healthy subjects were served as control group. The study population was divided into three groups according to disease severity: asymptomatic (n = 20), mild pneumonia group (n = 27) and a severe group (n = 11). During follow up nine (15.5%) patients required ICU admission and three of them were died eventually. Serum IL-18 were correlated with other inflammatory markers and biochemical markers of organ injury; creatinine, liver enzymes and troponin. Serum IL-18 levels were remarkably higher in COVID-19 patients compared to healthy subjects with being highest in severe pneumonia group (p < 0.001). IL-18 serum concentrations were almost four-fold higher in patients with worse outcome compared to good outcome (p < 0.001). Serum IL-18 above the cut off value of 576 pg/mL on admission was associated with 11.7 fold increased risk of ICU admission.ConclusionsThe serum concentrations of IL-18 correlate with other inflammatory markers and reflect disease severity. Results of the present study shed light on role of IL-18 on COVID-19 pathogenesis and might provide an evidence for the clinical trials on IL-18 antagonists for the treatment of severe COVID-19 patients.

Prognostic significance of serum galectin-3 in hospitalized patients with COVID-19

Effect of galectin-3, IL-1, IL-6 and TNF-alpha on disease prognosis and mortality in COVID-19 patients

Serum IL-6 and Procalcitonin Are Two Promising Novel Biomarkers for Evaluating the Severity of COVID-19 Patients.

Prognostic Utility of Galectin-3 for Recurrent Cardiovascular Events During Long-term Follow-up in Patients with Stable Coronary Heart Disease: Results of the KAROLA Study

Galectins can serve as biomarkers in COVID-19: A comprehensive systematic review and meta-analysis

Prediction of Severe Illness Due to COVID-19 Based on an Analysis of Initial Fibrinogen to Albumin Ratio and Platelet Count.

Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19

Research on Clinical Value of Galectin-3 in Evaluating the Prognosis of Acute Heart Failure.

Cytokines and Other Laboratory Parameters of Hospitalized COVID-19 Patients that Predict Intensive Care Unit Admission

Prognostic Value of Galectin-3 on Admission in Chinese Patients with Heart Failure: a Prospective Observational Study

Galectin-3 Predicts Long-Term Risk of Cerebral Disability and Mortality in Out-of-Hospital Cardiac Arrest Survivors

Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19

Serum transgelin is a novel prognostic biomarker for COVID-19 patients

Association between serum levels of GDF-15, suPAR, PIVKA-II, sdLDL and clinical outcomes in hospitalized COVID-19 patients

Serum galectin-3 and aldosterone: potential biomarkers of cardiac complications in patients with COVID-19

A New Laboratory Tool for COVID-19 Severity Prediction, CENIL Score

Potential Plasma Proteins (LGALS9, LAMP3, PRSS8 and AGRN) as Predictors of Hospitalisation Risk in COVID-19 Patients

Biomarker of severity in hospitalised patients with COVID-19: a retrospective study

LGALS9, LAMP3, PRSS8 and AGRN Predict Hospitalisation Risk in COVID-19 Patients

Evaluation and Prognostic Significance of Galectin-3 Expression in Oral Squamous Cell Carcinoma

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19